drugset / Trial / NCT03667300
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
RandomizedParallel-groupTriple-blindTreatment
Summary
In this multi-center, randomized, double-blind, active-controlled, phase II non-inferiority study, we aimed to test the non-inferiority of evogliptin vs linagliptin in terms of reduction of albuminuria at week 24 from baseline in patients with type 2 diabetes having renal insufficiency.
Timeline
- Start
- 2017-03-16
- Primary completion
- 2019-05-14
- Completion
- 2019-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Evogliptin | Small molecule | 5 mg | Oral |
| Comparator | Linagliptin | Small molecule | 5 mg | Oral |